92 documents

Read All
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million on June 28. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten...
Read More
14:48 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Zafgen's ZGN-1061 meets in Phase II for Type II diabetes

Zafgen Inc. (NASDAQ:ZFGN) said the 0.9 mg dose of subcutaneous ZGN-1061 every three days met the primary endpoint in a Phase II trial to treat Type II diabetes in patients failing multiple other antidiabetic agents....
Read More
18:41 , Jun 28, 2018 |  BC Extra  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million Thursday. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten by Leerink....
Read More
20:48 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Asieris raises series B round

Asieris Pharmaceuticals Co. Ltd. (Taizhou, China) said on Dec. 27, 2017, that it raised RMB110-RMB120 million ($16.8-$18.3 million) in a series B round led by Lapam Capital. Fellow new investors Kaitai Capital and Zhongguancun Qihang...
Read More
18:39 , Dec 29, 2017 |  BC Extra  |  Financial News

Asieris raises series B round

Asieris Pharmaceuticals Co. Ltd. (Taizhou, China) said it raised RMB110-RMB120 million ($16.8-$18.3 million) in a series B round led by Lapam Capital. Fellow new investors Kaitai Capital and Zhongguancun Qihang Industry Fund also participated, as...
Read More
20:02 , May 5, 2017 |  BC Week In Review  |  Clinical News

Zafgen's next-generation MetAP2 inhibitor well tolerated in Ph I

Zafgen Inc. (NASDAQ:ZFGN) said ZGN-1061 reduced subjects’ weight and was well tolerated with no serious adverse events reported in the 2-part Phase I ZAF-1061-101 trial in healthy volunteers and obese patients. Next half, the company...
Read More
23:10 , May 4, 2017 |  BC Extra  |  Clinical News

Zafgen plans Phase II trial of next-generation MetAP2

Zafgen Inc. (NASDAQ:ZFGN) added $0.81 (17%) to $5.68 in early after-hours trading Thursday after reporting results of a Phase I trial of ZGN-1061, its next-generation second-generation methionine aminopeptidase 2 (MetAP2) inhibitor. Next half, the company...
Read More
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc.’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research plan...
Read More
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Zafgen endocrine/metabolic news

Zafgen will reduce headcount by 47 (34%) to 31 and discontinue development of beloranib ( ZGN-440) to focus on developing ZGN-1061 to treat severe and complicated obesity. The cuts include President Patrick Loustau and...
Read More
07:00 , Jul 20, 2016 |  BC Extra  |  Company News

Zafgen sinks after ending beloranib program

Zafgen Inc. (NASDAQ:ZFGN) fell $3.51 (52%) to $3.24 on Wednesday after saying late Tuesday that it will discontinue development of subcutaneous beloranib (ZFN-440). Zafgen was studying the candidate to treat Prader-Willi syndrome and severe obesity...
Read More